Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

MONTREAL Canada & Boston MA, February 29, 2016 - Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today announced it has successfully completed its Phase 2, first-in-patients, dose ranging, clinical study of THR-184 for the prevention of acute kidney injury (AKI) in at risk patients undergoing cardiac surgery (NCT01830920). In the study, there was a reduction in the incidence of AKI in patients treated with the highest dose and THR-184 was safe and well tolerated.

Read more

Share